We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

54 hedge funds and large institutions have $40.2M invested in OncoMed Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 15

9% less capital invested

Capital invested by funds: $44.4M → $40.2M (-$4.13M)

14% less funds holding

Funds holding: 63 → 54 (-9)

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17

Holders
54
Holders Change
-9
Holders Change %
-14.29%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
17
Reduced
15
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NC
Nexthera Capital
New York
+$1.52M
2
ECM
Endurant Capital Management
California
+$525K
3
BC
Broadfin Capital
New York
+$479K
4
Primecap Management
Primecap Management
California
+$323K
5
EIM
Essex Investment Management
Massachusetts
+$231K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.23M
2
Ameriprise
Ameriprise
Minnesota
-$654K
3
First Eagle Investment Management
First Eagle Investment Management
New York
-$507K
4
CM
Crestline Management
Texas
-$483K
5
DGI
Disciplined Growth Investors
Minnesota
-$351K
Name Holding Trade Value Shares
Change 		Change in
Stake
Primecap Management
1
Primecap Management
California
$12.1M +$323K +135,000 +2%
BI
2
BVF Inc
California
$8.57M -$136K -56,600 -1%
PA
3
Perceptive Advisors
New York
$5.56M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$2.14M +$23.3K +9,716 +1%
Renaissance Technologies
5
Renaissance Technologies
New York
$1.73M +$144K +60,000 +8%
NC
6
Nexthera Capital
New York
$1.35M +$1.52M +634,715 New
SI
7
Sofinnova Investments
California
$839K -$1.2K -500 -0.1%
CS
8
Candriam SCA
Luxembourg
$806K – – –
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$696K +$4.55K +1,900 +0.6%
CC
10
Cannell & Co
New York
$643K – – –
BlackRock
11
BlackRock
New York
$510K +$7.34K +3,064 +1%
ECM
12
Endurant Capital Management
California
$465K +$525K +219,114 New
BC
13
Broadfin Capital
New York
$424K +$479K +200,000 New
Norges Bank
14
Norges Bank
Norway
$387K – – –
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$329K +$39K +16,263 +12%
BCM
16
Bridgeway Capital Management
Texas
$278K – – –
Geode Capital Management
17
Geode Capital Management
Massachusetts
$270K +$24.3K +10,150 +9%
BC
18
Birchview Capital
Vermont
$252K +$47.9K +20,000 +20%
Axa
19
Axa
France
$248K – – –
Connor, Clark & Lunn Investment Management (CC&L)
20
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$231K +$19.8K +8,252 +8%
EIM
21
Essex Investment Management
Massachusetts
$205K +$231K +96,639 New
SIM
22
Spark Investment Management
New York
$202K -$92.7K -38,700 -29%
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$200K +$226K +94,241 New
Jacobs Levy Equity Management
24
Jacobs Levy Equity Management
New Jersey
$180K +$498 +208 +0.2%
Bank of America
25
Bank of America
North Carolina
$178K -$3.36K -1,403 -2%
1
2 3

OMED Hedge Fund Activity: Q3 2018 in Review

54 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q3 2018, worth a combined $40.2M — down 9.3% from $44.4M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of OMED and 8 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 17 added.

The largest buyer was Nexthera Capital, opening a new position worth an estimated $1.52M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.23M sold.

  • 54 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q3 2018, down from 63 in Q2 2018.
  • Funds reported $40.2M of OncoMed Pharmaceuticals, Inc. stock for Q3 2018, down 9.3% quarter-over-quarter.
  • 8 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q3 2018 and 17 closed out, a net change of -9 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q3 2018 was Nexthera Capital, an estimated $1.52M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q3 2018 was Alyeska Investment Group, an estimated $1.23M sold.

Based on aggregated 13F filings for Q3 2018.